U.S. Hospitality Stock News

On December 18, 2025, VeriSign’s Executive Chairman, President, and CEO D Bidzos sold 9,000 company shares, contributing to a year of substantial insider selling highlighted in recent SEC filings. These transactions, set against VeriSign’s role in operating critical internet infrastructure, draw attention to how leadership’s trading activity aligns with its long-term outlook on the core domain registry business. We’ll now explore how this pattern of insider selling, particularly by the CEO,...

Cintas Corporation ( NASDAQ:CTAS ) came out with its second-quarter results last week, and we wanted to see how the...

Earlier this month, Talen Energy reshaped its leadership structure by appointing former CFO Terry L. Nutt as President and naming Cole Muller as Chief Financial Officer, alongside a series of senior operational and development role changes to support its evolving power and infrastructure business. The extensive reallocation of responsibilities, from nuclear oversight and fleet operations to new generation asset development and data center strategy, signals a concerted push to align...

Etsy, Inc. recently announced a new US$750 million share repurchase authorization, lifting its total approved buyback capacity to nearly US$1 billion and confirming Fred Wilson will become Lead Independent Director in January 2026 alongside a planned CEO transition. The combination of substantial buybacks and enhanced board oversight highlights Etsy’s emphasis on capital return and governance as it confronts slowing gross merchandise sales and buyer engagement. Now we’ll examine how Etsy’s...

Earlier this month, Citizens Financial Group reported that analysts expect its fiscal fourth-quarter 2025 diluted EPS to reach US$1.12, implying a very large year-over-year profit increase, after the bank topped Wall Street earnings estimates in each of the previous four quarters. The bank’s performance has been underpinned by expansion in its private bank and wealth franchise, strong capital markets activity, and tighter cost control supported by technology and private banking investments...

Earlier this year, Regencell Bioscience Holdings disclosed that the US Department of Justice had launched an investigation into trading of its shares and requested extensive operational, financial and accounting records, prompting the company to warn of potentially significant legal costs and penalties. The subsequent involvement of law firm Bronstein, Gewirtz & Grossman, LLC, which is examining potential claims on behalf of Regencell purchasers, adds another layer of legal uncertainty...

In recent days, Procter & Gamble’s Pantene brand expanded its influencer push by launching a limited‑edition “As seen in Alix’s Shower” Abundant & Strong kit with creator Alix Earle, while the company also confirmed the planned 2026 retirement of long‑time Health Care CEO Jennifer Davis. Together with prior announcements on European logistics expansion and portfolio pruning, these moves highlight how P&G is refining its brand reach while tightening its operational footprint. We’ll now...

Vera Therapeutics (VERA) has been on investors’ radar after upbeat analyst reports flagged two key drivers: rising revenue expectations for kidney drug candidate atacicept and a cash boost from a recent follow on equity raise. See our latest analysis for Vera Therapeutics. The upbeat story around atacicept and the recent equity raise is already showing up in the tape, with a roughly 80 percent 1 month share price return and a near doubling over three months. This builds on a strong 3 year...

Innoviva, Inc. recently received US FDA approval for NUZOLVENCE (zoliflodacin), a first-in-class, single-dose oral antibiotic to treat uncomplicated urogenital gonorrhea in adults and pediatric patients. This marks one of the first new FDA-approved treatments for gonorrhea in nearly twenty years, underscoring Innoviva’s role in addressing antibiotic resistance and unmet infectious disease needs. We’ll now explore how bringing a first-in-class, single-dose oral treatment for gonorrhea affects...

Core & Main (CNM) just checked several key boxes in its latest earnings update, pairing steady third quarter growth with a clear commitment to acquisitions, share buybacks and disciplined capital allocation. See our latest analysis for Core & Main. The stock has cooled slightly after the earnings pop, with a 1 month share price return of 18.01% and a 3 year total shareholder return of 181.16%. This suggests momentum is still firmly on Core & Main’s side. If this kind of steady execution...

Kinder Morgan (KMI) just tightened the picture for income investors, issuing fresh 2025 and 2026 profit guidance alongside plans for a higher 2026 dividend that extends its long running payout growth streak. See our latest analysis for Kinder Morgan. At a recent share price of $26.49, Kinder Morgan’s year to date share price return of minus 5.76 percent contrasts with its 5 year total shareholder return of 159.74 percent. This suggests that longer term income focused momentum remains firmly...

Institutional Buying and Upgraded Outlook Draw Investor Focus Laureate Education (LAUR) is back on investors radar after Formula Growth snapped up 111,000 shares, just as the company raised its full year outlook and expanded its buyback program. See our latest analysis for Laureate Education. The upgraded outlook, stronger enrollment trends, and larger buyback program appear to be feeding real momentum, with a roughly 86 percent year to date share price return and a 3 year total shareholder...

Elanco Animal Health recently received conditional FDA approval for Credelio Quattro-CA1, the first companion animal treatment for New World screwworm, while also advancing Befrena toward USDA approval and restructuring operations to cut costs and expand innovation capacity in the United States. Together with plans for tuck-in M&A and expanded monoclonal antibody manufacturing, these moves suggest Elanco is reshaping its pet health portfolio around higher-value, innovation-focused...

Madrigal Pharmaceuticals recently reported positive two-year Phase 3 MAESTRO-NAFLD-1 data for REZDIFFRA in compensated MASH cirrhosis and announced equity inducement awards for new employees, while also appointing industry veteran Rita Thakkar as its next Senior Vice President and Chief Accounting Officer effective January 12, 2026. These developments strengthen confidence in REZDIFFRA’s clinical profile and Madrigal’s financial governance, potentially reinforcing the company’s positioning...

Earlier this month, Pulse Biosciences received FDA Investigational Device Exemption approval to begin its NANOPULSE-AF clinical study of the nPulse Cardiac Catheter Ablation System in up to 145 patients with drug-resistant paroxysmal atrial fibrillation across as many as 30 global sites. This milestone, supported by ongoing European feasibility experience with 150 patients, moves the company’s nsPFA cardiac platform into a pivotal phase of clinical validation with potential implications for...

Earlier this month, Aymium announced a memorandum of understanding with Weyerhaeuser to form TerraForge Biocarbon Solutions, a joint venture that will use Weyerhaeuser-supplied wood fiber to produce up to 1.5 million tons of metallurgical-grade biocarbon annually as a coal replacement in metals production. This partnership links Weyerhaeuser’s timberland and mill footprint with Aymium’s low-emissions biocarbon technology, potentially opening a new long-term revenue stream tied to...

Centene (CNC) is back in the spotlight after a sharp selloff tied to two pressure points: fresh doubts over Affordable Care Act subsidies and new legal scrutiny of its withdrawn 2025 outlook. See our latest analysis for Centene. That backdrop helps explain why, despite a solid 90 day share price return of 19.14% from a recent low, Centene’s year to date share price return of negative 35.51% and three year total shareholder return of negative 52.20% show momentum has been fragile rather than...

Earlier in December 2025, PTC Therapeutics Canada ULC reported that Health Canada approved Sephience (sepiapterin) to treat sepiapterin-responsive phenylketonuria (PKU) and hyperphenylalaninemia (HPA) in patients 1 month and older, following supportive Phase 3 APHENITY data and making the therapy commercially available nationwide. This Canadian approval, coming soon after U.S. and European authorizations, further broadens Sephience’s global reach in a rare disease niche where regulatory...

New government subsidies for renewable projects have put Solaris Energy Infrastructure (SEI) in the spotlight, as its expansion strategy and recent mergers and acquisitions line up neatly with this policy tailwind. See our latest analysis for Solaris Energy Infrastructure. That backdrop seems to be feeding into sentiment, with SEI’s share price at $44.96 after a 4.41 percent 1 day share price return and a 52.67 percent year to date share price return. Its 5 year total shareholder return of...

PACCAR (PCAR) shares have quietly climbed about 14% over the past 3 months, easily outpacing the broader market. That steady move has investors rethinking what they are willing to pay for this trucking heavyweight. See our latest analysis for PACCAR. That move comes on top of a solid year, with an 8 percent year to date share price return and a powerful 5 year total shareholder return of about 136 percent. This signals that momentum is still firmly on PACCAR’s side as investors price in...

Baird’s downgrade of Lineage (LINE) to Neutral has put fresh pressure on a stock already down sharply this year, crystallizing growing concerns about near term performance and investor patience. See our latest analysis for Lineage. That downgrade lands after a tough stretch, with a year to date share price return of minus 41.5% and a 1 year total shareholder return of minus 39.1%. This shows momentum has clearly been fading despite Lineage’s scale and growth profile. If this shift in...

Masco (MAS) has quietly lagged the market this year, with the stock down about 11% over the past 12 months even as earnings and revenue keep grinding higher. That disconnect is worth unpacking. See our latest analysis for Masco. Despite the recent wobble, with a 1 day share price return of minus 1.52 percent and a 90 day share price return of minus 10.42 percent, Masco’s 3 year total shareholder return of 43.75 percent shows the longer term trend is still constructive rather than broken. If...

As the United States market kicks off a holiday-shortened week, major stock indexes like the S&P 500, Nasdaq, and Dow Jones Industrial Average have shown gains, buoyed by advances in tech shares and record highs in gold and silver. Amidst this positive momentum, investors are keenly focused on identifying stocks that may be trading below their intrinsic value, presenting potential opportunities for those looking to capitalize on undervalued assets.

As the U.S. stock market begins a holiday-shortened week with gains across major indexes, driven by advancements in tech shares and record highs in gold and silver, investors are keenly observing the shifts and opportunities within this vibrant economic landscape. In such an environment, growth companies with significant insider ownership can offer unique insights into potential long-term value creation, as insiders often have strong confidence in their firm's prospects.